Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extensionResearch in context

Summary: Background: In the CALCIPHYX trial, we investigated hexasodium fytate, an inhibitor of vascular calcification, for the treatment of calcific uraemic arteriolopathy (calciphylaxis), a rare condition characterised by painful, non-healing skin lesions. Methods: In this international, phase 3,...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Smeeta Sinha, Sagar U. Nigwekar, Vincent Brandenburg, Lisa J. Gould, Thomas E. Serena, Sharon M. Moe, George R. Aronoff, Dinesh K. Chatoth, Jeffrey L. Hymes, Kevin J. Carroll, Gabriela Alperovich, Laurence H. Keller, Joan Perelló, Alex Gold, Glenn M. Chertow
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-09-01
Serija:	EClinicalMedicine
Teme:	Calciphylaxis Calcific uraemic arteriolopathy Dialysis SNF472 Hexasodium fytate Calcification
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2589537024003638
Oznake:	Označite Brez oznak, prvi označite!